BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DEMENTIA RESEARCHER - ECPv6.14.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DEMENTIA RESEARCHER
X-ORIGINAL-URL:https://www.dementiaresearcher.nihr.ac.uk
X-WR-CALDESC:Events for DEMENTIA RESEARCHER
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/London
BEGIN:DAYLIGHT
TZOFFSETFROM:+0000
TZOFFSETTO:+0100
TZNAME:BST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0100
TZOFFSETTO:+0000
TZNAME:GMT
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/London:20250930T150000
DTEND;TZID=Europe/London:20250930T160000
DTSTAMP:20260614T004603
CREATED:20250911T082616Z
LAST-MODIFIED:20250911T082616Z
UID:10001915-1759244400-1759248000@www.dementiaresearcher.nihr.ac.uk
SUMMARY:Imaging Alzheimer's Before Symptoms Emerge
DESCRIPTION:We find ourselves in an exciting time in Alzheimer’s Disease (AD) research. As a result of longitudinal studies revealing amyloid and tau dynamics\, we now have disease-modifying treatments demonstrating cognitive benefit in early symptomatic individuals. There may be even more benefit if these therapies could be administered earlier\, before cognitive impairment.  \nMedical imaging plays a pivotal role in understanding the disease during this presymptomatic period when cognitive changes are subtle and difficult to detect. It’s important to stay current on the latest research about how these biomarkers are changing: both in terms of when (stage of the disease) and where (affected areas in the brain) and how these findings could impact your clinical development programs. \nIn this webinar\, Perceptive’s Professor David Cash will present how novel imaging and trial designs are improving accessibility and precision in presymptomatic AD research\, including: \n– How changes in amyloid burden\, tau deposition and atrophy can be detected during the presymptomatic phase of AD\n– How ultra low-field MRI and rapid MRI techniques can increase accessibility to imaging both in clinical research and in clinical trials\n– How new trial designs are needed to define relevant treatment effects in presymptomatic AD \nJoin us to learn how imaging biomarkers can detect Alzheimer’s decades before symptoms\, supporting earlier intervention and innovative trial designs. \n\nRegister to Attend
URL:https://www.dementiaresearcher.nihr.ac.uk/event/imaging-alzheimers-before-symptoms-emerge/
LOCATION:Online\, United Kingdom
CATEGORIES:Online
ATTACH;FMTTYPE=image/png:https://www.dementiaresearcher.nihr.ac.uk/wp-content/uploads/2025/09/Perceptive-logo.png
END:VEVENT
END:VCALENDAR